RBC Capital Maintains Outperform on HOOKIPA Pharma, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained an Outperform rating on HOOKIPA Pharma (NASDAQ:HOOK) but has reduced the price target from $6 to $5.
January 30, 2024 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital analyst Brian Abrahams maintains an Outperform rating on HOOKIPA Pharma but lowers the price target from $6 to $5.
The reduction in price target may cause some investors to adjust their valuation models, potentially leading to short-term price fluctuations. However, the maintenance of an Outperform rating suggests that the analyst still sees positive fundamentals or potential in the company, which could mitigate any negative impact from the price target adjustment.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100